MedTrace Logo

Sirolimus Discontinuation Strategies in Kaposiform Hemangioendothelioma

NCT07131644 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-09-08

No results posted yet for this study

Summary

Sirolimus has demonstrated efficacy in the treatment of kaposiform hemangioendothelioma (KHE); however, a high rate of rebound growth following discontinuation has been reported, highlighting the clinical importance of establishing an appropriate withdrawal regimen.

Conditions

  • Kaposiform Hemangioendothelioma

Interventions

DRUG

Sirolimus

Comparison of different sirolimus discontinuation strategies.

Sponsors & Collaborators

  • West China Hospital

    lead OTHER

Principal Investigators

  • Yi Ji, PhD · Sichuan University West China Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-13
Primary Completion
2027-09-01
Completion
2028-02-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07131644 on ClinicalTrials.gov